

THE JOURNAL OF
CLINICAL PSYCHIATRY

VOLUME 64

2003

SUPPLEMENT 12

S U P P L E M E N T

The Expert Consensus Guideline Series
**Optimizing Pharmacologic Treatment
of Psychotic Disorders**

Editors for the Guidelines

*John M. Kane, Stefan Leucht,
Daniel Carpenter, and John P. Docherty*

Expert Consensus Guideline Series

**Optimizing
Pharmacologic Treatment
of Psychotic Disorders**

John M. Kane, M.D.

*The Zucker Hillside Hospital and
the Albert Einstein College of Medicine*

Stefan Leucht, M.D.

*The Zucker Hillside Hospital and
Psychiatrische Klinik, Technische Universität München*

Daniel Carpenter, Ph.D.

Comprehensive NeuroScience, Inc.

John P. Docherty, M.D.

Comprehensive NeuroScience, Inc.

Editing and Design. Ruth Ross, M.A., David Ross, M.A., M.C.E., Ross Editorial

Acknowledgments. The authors thank Paola Vega, of Expert Knowledge Systems, for managing the data collection.

Reprints. Reprints may be obtained by sending requests with a shipping/handling fee of \$19.95 per copy to: Expert Knowledge Systems, 21 Bloomingdale Road, White Plains, NY 10605. For pricing on bulk orders of 50 copies or more, please call Expert Knowledge Systems at (914) 997-4005. For more information on the Expert Consensus Guidelines, visit www.psychguides.com.

Disclaimer. Any set of guidelines can provide only general suggestions for clinical practice and practitioners must use their own clinical judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. There is no representation of the appropriateness or validity of these guideline recommendations for any given patient. The developers of the guidelines disclaim all liability and cannot be held responsible for any problems that may arise from their use.

Copyright ©2003 by Expert Knowledge Systems, LLC, all rights reserved.

PUBLISHED BY PHYSICIANS POSTGRADUATE PRESS, INC.

THE JOURNAL OF CLINICAL PSYCHIATRY

VOLUME 64

2003

SUPPLEMENT 12

OPTIMIZING PHARMACOLOGIC TREATMENT OF PSYCHOTIC DISORDERS

- 4 Expert Consensus Panel.
 - 5 Introduction: Methods, Commentary, and Summary.
-

GUIDELINES

- 20 Guideline Organization and Key Terms.
 - I. MEDICATION SELECTION, DOSING, AND DOSE EQUIVALENCE
 - 21 Guideline 1: Selecting Initial Pharmacologic Treatment for a Psychotic Disorder.
 - 23 Guideline 2: Adequate Dose of Antipsychotics.
 - 24 Guideline 3: Therapeutic Drug Monitoring (Using Plasma Levels).
 - 24 Guideline 4: Duration of an Adequate Trial.
 - 25 Guideline 5: Dose Equivalency.
 - 27 Guideline 6: Dose Adjustment.
 - 29 Guideline 7: Strategies When There Is an Inadequate Response.
 - 35 Guideline 8: Pharmacologic Strategies for Managing Relapse.
 - 37 Guideline 9: Dose Adjustment in Stable Patients.
 - 38 Guideline 10: Managing Complicating Problems.
 - II. COMPLIANCE (ADHERENCE)
 - 42 Guideline 11: Levels of Compliance.
 - 42 Guideline 12: Assessing Compliance.
 - 43 Guideline 13: When to Intervene for Compliance Problems.
 - 43 Guideline 14: Strategies for Addressing Compliance Problems.
 - III. LONG-ACTING INJECTABLE ANTIPSYCHOTICS
 - 46 Guideline 15: Benefits of Long-Acting Injectable Antipsychotics.
 - 46 Guideline 16: Potential Disadvantages of Long-Acting Injectable Antipsychotics.
 - 47 Guideline 17: Factors Favoring Use of Long-Acting Injectable Antipsychotics.
 - 48 Guideline 18: Indications for Switching From an Oral Antipsychotic to a Long-Acting Injectable Atypical.
 - 49 Guideline 19: Factors Motivating Patients to Return for Repeat Injections.
 - IV. DEFINING REMISSION AND RECOVERY
 - 50 Guideline 20: Indicators of Remission and Recovery.
 - 51 Guideline 21: Severity and Duration of Symptoms as Indicators of Remission and Recovery.
-

SURVEY RESULTS

- 52 Expert Survey Results and Guideline References.
-

CME SECTION

- 95 Commentary: Expert Consensus Guidelines for Optimizing Pharmacologic Treatment of Psychotic Disorders.
 - 98 CME Posttest.
 - 100 CME Registration Form.
-

The Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders

The following participants in the Expert Consensus Survey were identified from several sources: recent research publications and funded grants, the DSM-IV advisers for psychotic disorders, the Task Force for the American Psychiatric Association's *Practice Guideline for the Treatment of Patients with Schizophrenia*, those who have worked on other schizophrenia guidelines, and participants in previous Expert Consensus Surveys on psychotic disorders. Of the 50 experts to whom we sent the schizophrenia survey, 47 (94%) replied. The recommendations in the guidelines reflect the aggregate opinions of the experts and do not necessarily reflect the opinion of each individual on each question.

Jorge L. Armanteros, M.D.
University of Miami

Ross J. Baldessarini, M.D.
Harvard Medical School

Nigel Bark, M.D.
Bronx Psychiatric Center

Robert Buchanan, M.D.
University of Maryland & Maryland Psychiatric Research Center

Peter F. Buckley, M.D.
Medical College of Georgia

William Carpenter, M.D.
University of Maryland & Maryland Psychiatric Research Center

Daniel E. Casey, M.D.
Oregon Health & Science University

Guy Chouinard, M.D.
Hopital L-H Lafontaine

Robert R. Conley, M.D.
University of Maryland Baltimore

John G. Csernansky, M.D.
Washington University School of Medicine

David G. Daniel, M.D.
Bioniche Development, Inc.

Michael Davidson, M.D.
Tel-Aviv University

John M. Davis, M.D.
University of Illinois

Lisa Dixon, M.D., M.P.H.
University of Maryland & VA Capitol Health Care Network MIRECC

Michael A. Flaum, M.D.
Iowa Consortium for Mental Health

Rohan Ganguli, M.D.
Western Psychiatric Institute, University of Pittsburgh Medical Center

David L. Garver, M.D.
University of Louisville

Steven Geisler, M.D.
The Zucker Hillside Hospital

John H. Gilmore, M.D.
University of North Carolina

Donald C. Goff, M.D.
Massachusetts General Hospital

Rona J. Hu, M.D.
Stanford University School of Medicine

Paul E. Keck, Jr., M.D.
University of Cincinnati College of Medicine

Samuel Keith, M.D.
University of New Mexico

Matcheri S. Keshavan, M.D.
University of Pittsburgh

John Krystal, M.D.
Yale University School of Medicine

John Lauriello, M.D.
University of New Mexico

Robert Paul Liberman, M.D.
UCLA School of Medicine

Jean-Pierre Lindenmayer, M.D.
NYU School of Medicine

Stephen Marder, M.D.
West LA Healthcare Center

Joseph McEvoy, M.D.
Duke University Medical Center

Alan Mendelowitz, M.D.
The Zucker Hillside Hospital

Alexander Miller, M.D.
University of Texas Health Science Center at San Antonio

Del D. Miller, M.D, Pharm.D.
University of Iowa

Henry A. Nasrallah, M.D.
University of Cincinnati

John Newcomer, M.D.
Washington University School of Medicine

Gary Remington, M.D.
University of Toronto

Samuel C. Risch, M.D.
University of California at San Francisco

Del Robinson, M.D.
Albert Einstein College of Medicine

Nina Schooler, M.D.
The Zucker Hillside Hospital

George Simpson, M.D.
University of Southern California at Los Angeles

Samuel B. Siris, M.D.
The Zucker Hillside Hospital

Thomas E. Smith, M.D.
Columbia University College of Physicians & Surgeons

Rajiv Tandon, M.D.
University of Michigan

Jan Volavka, M.D.
New York University

Peter J. Weiden, M.D.
SUNY Downstate Medical Center

Donna Wirshing, M.D.
UCLA School of Medicine

William C. Wirshing, M.D.
UCLA School of Medicine